Breaking News

Ultragenyx Appoints CMO

July 23, 2014

Agarwal to head clinical operations

Sunil Agarwal, M.D. has been appointed chief medical officer and senior vice president at Ultragenyx Pharmaceuticals, effective August 25, 2014. Dr. Agarwal will provide strategic leadership for clinical operations, clinical development, regulatory affairs, biometrics, pharmacovigilance, and non-clinical research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's chief executive officer, and will serve on the senior management team.
 
Dr. Agarwal most recently served as senior vice president and global head of clinical development for immunology and infectious diseases, metabolism, neuroscience, and ophthalmology at Genentech. Dr. Agarwal also served as senior vice president for immunology and infectious diseases, and vice president for rheumatology while at Genentech. Prior to the integration with Roche, he served as vice president of Genentech Drug Safety and held positions of increasing responsibility in the immunology clinical organization. Dr. Agarwal also held positions with MedImmune, Guilford Pharmaceuticals, and Kosan Biosciences.  
 
"On behalf of the Board of Directors and the Executive team, I am pleased to announce the addition of Dr. Agarwal to the Ultragenyx team. With over 15 years in the biotechnology industry in progressive leadership roles, his clinical development expertise and proven track record make him an excellent fit to achieve our mission of developing novel treatments for rare and ultra-rare diseases," said Dr. Kakkis. "Dr. Agarwal's appointment reflects the strength of our clinical stage pipeline and he will join our senior team to help lead the execution of our development programs."
 

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks